Zanetti A, Zatta A, Prosdocimi M, Dejana E
Eur J Pharmacol. 1986 Aug 22;128(1-2):119-27. doi: 10.1016/0014-2999(86)90565-0.
The effect of AD6 (8-monochloro-3-beta-diethylamino-ethyl-4-methyl-7- ethoxycarbonylmethoxycoumarin) was studied in vitro on washed human platelet aggregation and beta-thromboglobulin (beta TG) release induced by PAF alone or in combination with epinephrine. AD6 caused concentration-dependent inhibition of aggregation and beta TG release. Acetylsalicylic acid and the ADP scavenger apyrase were ineffective on the same parameters, while the specific PAF antagonist CV 3988, the Ca2+ antagonist diltiazem and the cyclo-oxygenase-lipoxygenase inhibitors nordihydroguaiaretic acid and BW 755C inhibited aggregation. The results indicate that AD6 is an inhibitor of platelet aggregation in vitro with a mode of action different from cyclo-oxygenase blockade.
研究了AD6(8-氯-3-β-二乙氨基乙基-4-甲基-7-乙氧羰基甲氧基香豆素)在体外对单独使用PAF或与肾上腺素联合使用时诱导的洗涤人血小板聚集和β-血小板球蛋白(βTG)释放的影响。AD6引起聚集和βTG释放的浓度依赖性抑制。乙酰水杨酸和ADP清除剂腺苷三磷酸双磷酸酶对相同参数无效,而特异性PAF拮抗剂CV 3988、Ca2+拮抗剂地尔硫卓以及环氧化酶-脂氧合酶抑制剂去甲二氢愈创木酸和BW 755C抑制聚集。结果表明,AD6是一种体外血小板聚集抑制剂,其作用方式不同于环氧化酶阻断。